Literature DB >> 2736988

Prophylactic treatment of postperfusion bleeding using EACA.

A J DelRossi1, A C Cernaianu, S Botros, G M Lemole, R Moore.   

Abstract

To determine the effects of prophylactic treatment with EACA for blood loss after cardipulmonary bypass surgery, 350 consecutive patients undergoing open-heart surgery were studied. One hundred seventy patients received an initial dose of 5 g of EACA prior to skin incision, followed by intravenous administration of 1 g/h for the next 6 to 8 h. The control group received saline solution in the same fashion. The EACA-treated group had decreased chest tube blood loss 24 h postoperatively. In addition, EACA-treated patients had fewer myocardial infarctions, cerebrovascular accidents or reoperations for bleeding. Treated patients needed fewer units of blood transfusions than the nontreated group. There was no incidence of hyperthrombotic state or other side effects in the EACA-treated group. We concluded that prophylactic treatment with EACA for open-heart surgery requiring extracorporeal circulation may reduce the total blood loss and the number of blood transfusions in a safe and tolerable manner.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736988     DOI: 10.1378/chest.96.1.27

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass.

Authors:  Y Uozaki; G Watanabe; K Kotou; K Ueyama; Y Doi; T Misaki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-05

2.  The stratification of cardiac surgical procedures according to use of blood products: a retrospective analysis of 1480 cases.

Authors:  J F Hardy; J Perrault; N Tremblay; D Robitaille; R Blain; M Carrier
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

3.  Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.

Authors:  Michael P Eaton; George M Alfieris; Dawn M Sweeney; Ronald E Angona; Jill M Cholette; Charles Venuto; Brian Anderson
Journal:  Anesthesiology       Date:  2015-05       Impact factor: 7.892

Review 4.  Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency.

Authors:  J F Hardy; S Bélisle
Journal:  Can J Anaesth       Date:  1994-11       Impact factor: 5.063

Review 5.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 6.  Antifibrinolytic therapy in cardiac surgery.

Authors:  R H Chen; O H Frazier; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

Review 7.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 8.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 9.  Natural and synthetic antifibrinolytics in cardiac surgery.

Authors:  J F Hardy; J Desroches
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

Review 10.  Limiting excessive postoperative blood transfusion after cardiac procedures. A review.

Authors:  V A Ferraris; S P Ferraris
Journal:  Tex Heart Inst J       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.